HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition of women’s health leader Organon. With its $11.75 billion buyout, Sun has picked up a drugmaker that matched the $6.2 billion in sales that it generated in 2025.

By FiercePharma · Apr 28, 2026 · via FiercePharma
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
dealsformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
DealsFiercePharma ↗
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big …
Apr 27, 2026
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
DealsFierceBiotech ↗
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
McKesson has let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo…
Apr 27, 2026
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
DealsEndpoints News ↗
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosi…
Apr 27, 2026